Erkim Pharmaceuticals

What Erkim Pharmaceuticals does

Er-Kim is a privately held, family-owned pharmaceutical commercialization company founded in 1981 in Istanbul, Turkey, and currently led by third-generation family executives Mert Zorlular (Chairman) and Cem Zorlular (CEO). The company specializes exclusively in commercializing rare and specialty medicines on behalf of growth-stage biotech companies that lack their own EMEA infrastructure, with 100% of revenue derived from self-launched partner assets. Er-Kim operates as the sole commercial partner across 49 emerging EMEA markets spanning Central and Eastern Europe, South Europe, MENA, and Eurasia/CIS, providing integrated regulatory affairs, market access, medical affairs, pharmacovigilance, and specialty supply chain capabilities through a single-operator model with no distributor handoffs.

The company's core technology infrastructure consists of three integrated layers: (1) a 49-market direct commercial entity network with embedded regulatory intelligence and pricing precedents built over 45 years; (2) a consolidated global logistics hub in Sofia, Bulgaria, offering temperature-controlled and cryogenic (-80°C) handling for ATMPs and gene therapies; and (3) a 16-function integrated organization spanning pre-launch (7 functions), launch execution (6), and post-launch (3) activities. Er-Kim's partner portfolio of 40+ global biotech leaders includes Ascendis Pharma, LEO Pharma, Egetis, Sentynl, Immunocore, Puma Biotechnology, Polaris Pharmaceuticals, Pharmanovia, and Orchard Therapeutics, with 68+ products currently distributed across 50+ countries and 100+ innovative medicines launched since inception.

Revenue is generated through multi-year exclusive distribution and commercialization agreements (transaction fees) and Early Access Programs (managed services), with disclosed revenue of EUR 305M+ in 2025 and a EUR 390M+ projection for 2026. The company employs 400+ professionals and maintains ISO 9001, ISO 27001, ISO 37001, GDP, GVP, and TRACE certifications. Er-Kim reports an average 2.4-month time from agreement to first commercial patient access and 17 markets activated within 12 months from first sale, positioning itself as a structural alternative to multinational pharma's own commercialization infrastructure for emerging EMEA.

Name

Erkim Pharmaceuticals

Legal name

Er-Kim İlaç Sanayi ve Ticaret Anonim Şirketi

Website

https://er-kim.com

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

101–250 employees

Short description

Er-Kim is a family-owned pharmaceutical commercialization partner serving growth-stage biotech companies with rare and specialty medicines across 49 emerging EMEA markets, operating 16 integrated functions from regulatory affairs through cryogenic supply chain via a single-operator model with no distributor handoffs.

Ownership category

akta.pro rank

Headquarters

HQ city

Besiktas

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Distribution and Commercialization Fees: Er-Kim earns revenue by serving as exclusive commercial partner for biotech products across EMEA markets. Revenue is 100% driven by self-launched assets from biotech partners. Income generated through distribution agreements, commercialization services, and partnership structures aligned with partner success.
2. Early Access Programs: Named patient supply, compassionate use programs, and cohort early access programs operate across 50+ markets before formal product registration. Generates 1-3 years of patient access and revenue pre-launch.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Er-Kim serves as the exclusive pharmaceutical commercialization and distribution partner for growth-stage biotech companies across 49 emerging EMEA markets. The company provides end-to-end commercialization infrastructure spanning regulatory affairs, market access, medical affairs, pharmacovigilance, and specialty supply chain, enabling biotech partners to launch rare disease and specialty medicines without building their own regional infrastructure. Revenue is generated through distribution agreements, commercialization fees, and early access programs tied to partner product success.

Product overview

Er-Kim operates as a pharmaceutical commercialization partner specializing in rare and specialty disease medicines across the EMEA region. The company does not develop a single unified product but rather offers a portfolio of distributed pharmaceutical products through exclusive commercialization and distribution agreements with global biotech partners. The product portfolio spans 68+ commercialized products including innovative therapies across 10 therapeutic areas: Oncology (15 conditions including LOQTORZI®, NERLYNX®, KIMMTRAK®), Neurology (15 conditions including Emcitate® for MCT8 deficiency), Hematology (6 conditions), Endocrinology & Metabolic Diseases (8 conditions including SKYTROFA®, YORVIPATH®, Vafseo®), Immunology (3 conditions), Dermatology (3 conditions including QRX003, Vyjuvek), Nephrology & Cardiology (4 conditions), Pain/Sleep/Addiction Medicine (4 conditions including Sunosi®), Ophthalmology (1 condition), and Advanced Therapies: Gene & Cell (3 conditions including Libmeldy, Vyjuvek, COLLAGENE). Services include Early Access Programs (EAP) for pre-commercialization named patient supply and compassionate use across 50+ markets. The company maintains a global operations infrastructure spanning 49 markets across Central & Eastern Europe (11), South Europe (10), MENA (16), and Eurasia/CIS (12), with headquarters in Istanbul, commercial hub in Athens, and logistics hub in Sofia.

Differentiator

Problem solved

Functional benefit

Products and services

• Early Access Programs (EAP)
• Exclusive Distribution and Commercialization Partnerships
• Specialty Pharmaceutical Distribution with Cryogenic Logistics
• Pharmacovigilance and Risk Management Services

Quantifiable outcome

• 2.4 months average time from agreement to first commercial patient access
• +4 more outcomes

Named customers10 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

20 partnerships are on record, tiered core, flagship, minor and historical.

• LEO Pharma A/ScoreChannel Partner/ Reseller/ Distributor · 14 April 2026Exclusive distribution agreement to commercialize LOQTORZI (toripalimab) for nasopharyngeal carcinoma and oesophageal squamous cell carcinoma across 11 CEE markets (Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia).
• Egetis Therapeutics ABcoreChannel Partner/ Reseller/ Distributor · 10 December 2025Expanded exclusive distribution agreement for Emcitate (tiratricol) for MCT8 deficiency across 16 countries in Central, Eastern, and Southeastern Europe. Initial agreement covered Türkiye in June 2025.
• Sentynl TherapeuticscoreChannel Partner/ Reseller/ Distributor · 24 September 2025Commercialization agreement for Nulibry (fosdenopterin) for MoCD Type A and Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome across 33 countries in Central and Eastern Europe, Mediterranean region, and Eurasia.
• CNX TherapeuticscoreChannel Partner/ Reseller/ Distributor · 26 August 2025Exclusive agreement to distribute oncology portfolio including Cardioxane and Savene (dexrazoxane) across Central and Eastern Europe and Türkiye.
• ImmunocorecoreChannel Partner/ Reseller/ Distributor · 30 June 2025Exclusive distribution and commercialization partnership for KIMMTRAK (tebentafusp) for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma across Turkey, MENA, Caucasus, and CIS regions.
• Puma BiotechnologycoreChannel Partner/ Reseller/ Distributor · 30 April 2025Exclusive distribution agreement for NERLYNX (neratinib) for HER2-positive breast cancer across 10 countries in Eastern Europe and Central Asia (Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, Uzbekistan).
• Polaris PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 15 April 2025Exclusive distribution agreement for pegargiminase (ADZODI) for malignant pleural mesothelioma across 36 markets in EMEA covering Central and Eastern Europe, Eurasia, North Africa, and the Mediterranean.
• PharmanoviacoreChannel Partner/ Reseller/ Distributor · 21 February 2025Exclusive distribution partnership for Sunosi (solriamfetol) for Excessive Daytime Sleepiness across 14 CEE markets (Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, Slovenia).
• MEDICE Health FamilycoreChannel Partner/ Reseller/ Distributor · 14 January 2025Exclusive distribution agreement for Vafseo (vadadustat) for anemia in chronic kidney disease patients on dialysis across 8 CEE markets (Bulgaria, Croatia, Czechia, Hungary, Poland, Romania, Slovakia, Slovenia).
• Orchard Therapeutics (Kyowa Kirin)coreChannel Partner/ Reseller/ Distributor · 7 October 2024Partnership to broaden access to Libmeldy (atidarsagene autotemcel) gene therapy for metachromatic leukodystrophy to eligible patients in Turkey and certain Eurasian countries. Identifies children with MLD and refers to European treatment centers.
• Ascendis Pharma A/SflagshipChannel Partner/ Reseller/ Distributor · 8 January 2024Exclusive distribution agreement for SKYTROFA (lonapegsomatropin), YORVIPATH (palopegteriparatide), and TransCon CNP across 21 countries in CEE and Turkey. Extended in December 2024 to add 8 Eurasian markets. Became first partner to expand across all four Er-Kim geographies (CEE, South Europe, Eurasia, MENA).
• Nabriva TherapeuticsminorChannel Partner/ Reseller/ Distributor · 18 July 2022Exclusive distribution rights for XENLETA (lefamulin) for community-acquired bacterial pneumonia across 9 CEE markets with named patient access in up to 5 additional countries.
• Quoin PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 1 March 2022Extended exclusive distribution agreement for QRX003 investigational treatment for Netherton syndrome across 21 countries including Turkey, Georgia, Azerbaijan, Greece, Cyprus, and Malta.
• AnGeshistoricalChannel Partner/ Reseller/ Distributor · 1 January 2019Announced partnership to commercialize COLLATEGENE (HGF plasmid gene therapy for critical limb ischaemia)—Er-Kim's first gene therapy launch. Established regulatory, logistics, and patient-support framework for ATMP portfolio.
• CelgenehistoricalChannel Partner/ Reseller/ Distributor · 1 January 2004Launched THALIDOMIDE implementing first international Risk Management Programme in Turkey—controlled distribution framework for teratogenic drug. Foundation for all ATMP and restricted-distribution products since.
• Gilead ScienceshistoricalChannel Partner/ Reseller/ Distributor · 1 January 1996Launched AMBISOME (liposomal amphotericin B) through NeXstar Pharmaceuticals. Initiated multi-decade relationship spanning HIV, hepatitis, and beyond.
• Schering-PloughhistoricalChannel Partner/ Reseller/ Distributor · 1 January 1991Launched INTRON A (interferon alfa-2b) first disease-modifying therapy for hepatitis B and C in Turkey and wider region.
• Ferring PharmaceuticalshistoricalChannel Partner/ Reseller/ Distributor · 1 January 1990First foray into endocrinology and urology including desmopressin for diabetes insipidus and GnRH analogues. Proved model could operate across therapeutic areas.
• NycomedhistoricalChannel Partner/ Reseller/ Distributor · 1 January 1989Partnered to launch OMNIPAQUE iodinated contrast agent for CT scanning and angiography. Expanded beyond oncology into diagnostic infrastructure.
• Bristol-Myers SquibbhistoricalChannel Partner/ Reseller/ Distributor · 1 January 1984Partnered to launch CEENU (lomustine), VEPESID (etoposide), and MUTAMYCIN (mitomycin C) for oncology. Expanded oncology formulary from cytotoxic basics to multi-indication portfolio.

Scale indicators12 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Clinigen Group: UK-based specialty pharma services and unlicensed medicines distributor serving biotechs across international markets. Most directly comparable to Er-Kim's commercialization/distribution model with similar end markets (EMEA-focused biotech partnerships) and adjacent named-patient access programs.
• AOP Health (AOP Orphan Pharmaceuticals): Vienna-based specialty pharma focused on rare diseases and specialty medicines across CEE, South Europe, and emerging markets. Directly comparable business model of partnership-driven commercialization in overlapping geographies and therapy areas (rare disease, oncology).
• Inceptua Group: Luxembourg-based pharma services company providing pre-launch access programs, named-patient supply, and commercialization support to biotechs in international markets. Directly comparable to Er-Kim's early access programs and B2B pharma services model.
• Pharmanovia: UK-based specialty pharma that revitalizes, in-licenses, and commercializes established medicines globally. Directly comparable as a partner that both distributes partner products and operates its own specialty pharma assets across similar geographies.

Broad incumbents

• Sobi (Swedish Orphan Biovitrum): Listed Swedish rare-disease specialty pharma with strong European distribution and a partnership-heavy model. Overlaps with Er-Kim's rare-disease focus and EMEA commercial footprint, though Sobi owns assets rather than distributing on a pure service basis.
• Hikma Pharmaceuticals: Jordan-headquartered specialty and generics pharma with deep MENA distribution plus US and European operations. Comparable to Er-Kim's MENA-first commercial capability and emerging-market pricing/reimbursement expertise, though Hikma also manufactures.
• Recordati: Italian specialty pharma with a dedicated rare disease business and a long history of licensing in-assets for European commercialization. Overlaps with Er-Kim on rare disease partnership economics and Southern/Central European geography.
• STADA Arzneimittel: German generics and specialty pharma with established CEE and CIS distribution. Comparable emerging-EMEA commercial infrastructure and partnership-driven portfolio expansion, though broader in scope including generics.
• Aspen Pharmacare: South African specialty pharma with established emerging-market distribution across MENA, Latin America, and Asia. Comparable emerging-market commercialization focus and partnership-driven product acquisition strategy.

Regional players

• Polpharma Group: Polish pharma group with leading CEE distribution and active partnership/licensing model. Comparable as a CEE-focused pharma commercialization platform, though more concentrated geographically than Er-Kim's 49-market footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/erkimpharmaceuticals

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Erkim Pharmaceuticals